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 Th e excessive synthesis and secretion of 
parathyroid hormone (PTH) in patients 
with advanced stages of chronic kidney 
disease (CKD) and the secondary hyper-
parathyroidism that ensues remain a vex-
ing problem. Th is is particularly true for 
those patients who develop a severe form 
of the disease. For many years, the factors 
held mainly responsible for the increase in 
PTH production in CKD were a decrease 
in serum calcium, a reduction in 1,25-
di(OH)-vitamin D (calcitriol) synthesis by 
the kidney, and / or phosphate retention 
secondary to impaired renal excretion. 
 Since the cloning, more than a decade 
ago, of  klotho and subsequently  fi broblast 
growth factor 23 ( FGF23 ), their respective 
roles in calcium / phosphate metabolism 
have been progressively unraveled. (Note 
that the term  ‘ klotho ’ corresponds, strictly 
speaking, to   -klotho, as subsequently 
another form of klotho, named   -klotho, 
has been identifi ed.) Deletions of  klotho 
and  FGF23 lead to similar phenotypes in 
the mouse, characterized by systemic fea-
tures linked to accelerated aging, and by 
biochemical and morphologic features 
partially resembling those of the mineral 
and bone disorder of CKD (CKD-MBD). 
In particular, both  FGF23   −  /  −   and 
 klotho   −  /  −   mice develop hyperphos-
phatemia, vascular calcifi cation, and oste-
openia. In addition, plasma calcitriol is 
elevated, unlike what is usually observed 
in CKD-MBD except when high doses of 
active vitamin D derivatives are adminis-
tered. It is clear at present that both klotho 
and FGF23 play an active role in the phys-
iological control of mineral homeostasis 
and in the disturbances of calcium and 
phosphate metabolism characteristic of 
CKD-MBD. 
 On the basis of recent fi ndings, FGF23 
requires the presence of klotho in order to 
transform two of the four identifi ed FGF 
receptors (FGFR1 through FGFR4) with 
low affi  nity for the hormone into recep-
tors with high affi  nity, specifi cally sub-
types IIIC of both FGFR1 and FGFR3. 
According to this theory, klotho functions 
as an obligatory co-receptor, although 
there are exceptions to this rule (see 
below).  Klotho is expressed mainly in the 
kidney and the parathyroid gland, two 
organs with major importance for the 
regulation of calcium / phosphate metabo-
lism. Its gene product is further expressed 
in the choroid plexus of the brain and, 
in addition, at very low levels in other 
tissues, including the liver, duodenum, 
pancreas, muscle, gonads, brain, and 
adipose tissue. 
 Th e main cooperative actions of FGF23 
and klotho in the kidney consist of an 
inhibition of proximal tubular phosphate 
reabsorption (like the eff ect of PTH), and 
an inhibition of 25(OH)-vitamin D 1  -
hydroxylase (opposite to the effect of 
PTH), via an interaction with FGFRs 1, 3, 
and / or 4. Th e specifi c FGFR involved in 
FGF23 and klotho interaction to inhibit 
tubular phosphate reabsorption remains 
a matter of debate.  klotho is expressed only 
in the distal tubule. Colocalization of 
FGFR1 and klotho in the distal tubule 
suggests that this site may be an eff ector 
site of FGF23. 1 However, the main, if not 
exclusive, site of phosphate reabsorption 
in the kidney is the proximal tubule. Th is 
site expresses only FGFR3, not FGFR1, 
FGFR2, or FGFR4. One of the possible 
explanations for this apparent paradox is 
an intrarenal or extrarenal shuttle of the 
secreted extracellular form of klotho —
 probably as the full-length extracellular 
domain of its two internal repeat 
sequences, KL1 and KL2, detected in 
blood — and its subsequent binding to 
FGFR3 in the proximal tubule. 
 Interestingly, the KL1 and KL2 repeats 
of klotho each share amino acid sequence 
homology to family 1 glycosidases. Th e 
discovery of this homology paralleled the 
discovery of additional, probably FGF23-
independent functions of klotho, includ-
ing the regulation of the Ca 2  +   channel 
TRPV5 and the K   +   channel ROMK in the 
distal tubule, the Ca 2  +   channel TRPC6 in 
the heart, vascular smooth muscle and 
glomerular function; and of other proc-
esses such as insulin and insulin-like 
growth factor signaling and Na   +   / K   +   -
ATPase activity. 2 More recently, it has been 
found that klotho appears to function as a 
sialidase rather than a glycosidase and 
thereby leads to an increase in the cell-
surface abundance of these ion channels, 
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via binding to galectin-1 as far as TRPV5 
is concerned. 3 Interestingly, internaliza-
tion of ROMK and that of TRPV5 occur 
via different pathways, the former by 
clathrin-coated vesicles, the latter by 
caveolae. 4,5 
 Th e role of FGF23 and klotho in the 
parathyroid gland is more complex. Para-
thyroid tissue expresses the gene products 
of  FGFR1 ,  FGFR3 , and  klotho . FGF23 
therefore could exert direct eff ects on the 
parathyroid, via cooperation with klotho 
at the receptor level as mentioned above. 
Studies have indeed shown a direct inhib-
itory eff ect of FGF23 on parathyroid gland 
FGFR signaling in animals  in vivo and 
 ex vivo , 6 and on PTH mRNA expression 
and protein secretion in bovine para-
thyroid cells  in vitro . 7,8 Th e FGF23 eff ect 
in the latter might be direct or indirect, for 
example via stimulation of parathyroid 
25(OH)-vitamin D 1  -hydro xylase, in con-
trast to the inhibitory FGF23 eff ect on the 
same enzyme in the kidney. 
 Klotho can directly modulate para-
thyroid Na   +   / K   +   -ATPase, independently 
of FGF23, via a molecular interaction with 
the   1-subunit of this enzyme, as shown 
by Imura  et al. 9 Th is interaction supports 
the increase in the abundance of Na   +   / K   +   -
ATPase at the plasma membrane, which 
is stimulated by low extracellular Ca 2  +   , 
but inhibited by high extracellular Ca 2  +  
concentration. In  klotho -deleted mice the 
Na   +   / K   +   -ATPase-dependent stimulation 
of PTH secretion by low extracellular 
Ca 2  +   is negligible, compared with that in 
 klotho -suffi  cient wild-type mice. Accord-
ing to the authors ’ hypothesis, the result-
ing enhancement of Na   +   / K   +   -ATPase 
activity could create an electrochemical 
gradient that in turn would enhance PTH 
secretion. Alternatively, enhanced Na 
effl  ux could modify transepithelial Ca 2  +  
transport via the Na   +   / Ca 2  +   exchanger 
and thereby modify PTH secretion. 
 Somewhat surprisingly, patients with 
advanced stages of CKD generally have 
markedly increased serum FGF23 levels, 
together with high, not low, serum PTH 
levels. Th ere is actually abundant clinical 
and experimental evidence in favor of a 
positive association of circulating FGF23 
with PTH. In CKD, this could be attrib-
uted to chronic hyperphosphatemia, 
which has been shown to stimulate 
synthesis of both FGF23 by the bone and 
PTH by the parathyroid gland, via direct 
and indirect mechanisms. Moreover, the 
renal excretion of FGF23 could be 
impaired, leading to further increase in 
the serum. Treatment with active vitamin 
D derivatives also could explain high 
serum FGF23 levels, as calcitriol directly 
stimulates skeletal FGF23 secretion, 
together with persisting high serum PTH 
levels due to parathyroid resistance to the 
action of vitamin D sterols. 
 Mice overexpressing FGF23, with ini-
tially normal kidney function, exhibit 
high serum PTH levels and parathyroid 
hyperplasia. This association has been 
attributed to the inhibitory eff ect of FGF23 
on renal 25(OH)-vitamin D 1  -hydroxy-
lase and the ensuing decrease in circulat-
ing calcitriol, which leads to a decrease in 
intestinal calcium and phosphate absorp-
tion, a decrease in serum calcium, and 
thereby an increase in PTH secretion. 
 Another possibility could be a direct or 
indirect stimulation by hyperparathy-
roidism of FGF23 synthesis in the bone, 
as suggested by two observations of high 
serum FGF23 levels in association with 
hyperparathyroidism or pseudohyperpara-
thyroidism of nonrenal origin. 10,11 Th e 
fi rst patient had a chromosomal translo-
cation with increased serum klotho and 
PTH levels. Th e second had Jansen ’ s dis-
ease with constitutively activated PTH 
receptor 1 mimicking primary hyperpara-
thyroidism. 
 An interesting novel explanation for 
the absence of an inverse relation 
between serum FGF23 and PTH levels in 
patients with CKD has been provided by 
Komaba  et al. 12 Th ese authors observed 
a decrease in klotho and FGFR1 immu-
noreactivity and mRNA expression in 
parathyroid tissue of chronic hemodialy-
sis patients, particularly in nodular areas 
of the hyperplastic glands. In contrast, 
the expression of Ki67, a marker of cell 
proliferation, was upregulated. On the 
basis of their fi ndings, the authors postu-
lated the existence of relative parathyroid 
gland resistance to FGF23. Galitzer 
 et al. 13 provided experimental support 
for this postulate. Th ey found a decrease 
in parathyroid mRNA and protein 
expression of both klotho and FGFR1 in 
rats with chronic renal failure. Moreover, 
recombinant FGF23 failed to reduce 
serum PTH or to activate mitogen-
activated protein kinase signaling in the 
parathyroid glands of uremic rats  in vivo , 
and to inhibit PTH mRNA expression 
and PTH secretion by uremic rat para-
thyroid gland tissue  in vitro , in contrast 
to the expected inhibitory response in 
normal rat parathyroids. 
 Hofman-Bang  et al. 14 (this issue) now 
report the unexpected finding of an 
increase, not a decrease, in the gene 
expression of  klotho ,  FGFR1IIIC , and 
 Na   +   / K   +   -ATPase in the parathyroid glands 
of rats with chronic renal failure. Th eir 
observation appears to be in confl ict with 
those of Galitzer  et al. , 13 Komaba 
 et al. , 12 and Kumata  et al. , 15 although in 
agreement with that of Ohkido  et al. 16 Th e 
fi nding by Hofman-Bang  et al. 14 is coun-
terintuitive, since in presence of persist-
ently high serum PTH levels in CKD one 
would expect at least some degree of 
resistance to the action of FGF23, similar 
to the relative resistance of the parathyroid 
to extracellular Ca 2  +   and calcitriol. 
 Hofman-Bang  et al. 14 point out that in 
animal models the expression of  klotho and 
 FGFR1 in the parathyroid actually has been 
found to be variable, depending on the 
stage of CKD and the duration of the ure-
mic state. In the study by Galitzer  et al. , 13 
parathyroid  klotho expression was indeed 
signifi cantly increased aft er 2 weeks of ure-
mia but was subsequently suppressed at 
6 weeks of uremia, whereas  FGFR1 expres-
sion was decreased at both 2 and 6 weeks. 
 What other factors could explain these 
discrepant results? Findings in experi-
mental animals are not necessarily the 
same as those in human patients. Con-
cerning the discrepancy between the fi nd-
ings of their animal study and that of 
Galitzer  et al. , 13 Hofman-Bang  et al. 14 dis-
cuss diff erences in experimental models, 
in particular a different mode of CKD 
induction, as well as possible diff erences 
in diet composition. Th e markedly higher 
serum creatinine in the uremic rats of the 
study by Galitzer  et al. 13 could be part of 
the explanation. In line with this theory, 
dialysis patients with the most severe 
CKD and secondary hyperparathyroidism 
had an overall decrease in klotho expres-
sion, according to Komaba  et al. 12 and 
Kumata  et al. , 15 although the degree of 
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suppression also appeared to depend on 
the type of parathyroid-cell proliferation. 
Nodular, probably clonally growing areas 
of parathyroid tissue exhibited lower 
klotho and FGFR1 expression than dif-
fusely hyperplastic areas. 12 
 Th ere are other possible explanations. 
We do not have precise information on 
vitamin D status in these animal studies. 
Low serum calcitriol levels might favor 
high  klotho expression. In the work by 
Hofman-Bang  et al. , 14 parathyroid 
klotho expression was reduced by calci-
triol given to uremic rats on a high-
phosphate diet. This reduction was 
associated with a further increase in 
serum phosphate, rendering a major 
stimulatory role of high phosphate 
improbable  ipso facto . 
 As for FGFR expression, FGFR1 IIIC 
was upregulated but FGFR3 IIIC was 
unchanged in the uremic rats of Hofman-
Bang  et al. 14 In addition to diff ering ligand 
affi  nities and tissue distribution, the regu-
lation of FGFR subtype expression and 
post-receptor signaling might differ, 
depending on specifi c disturbances of cal-
cium and phosphate metabolism. 
 Finally, Hofman-Bang  et al. 14 make the 
attractive hypothesis that the observed 
upregulation of klotho could be part of an 
Na   +   / K   +   -ATPase-driven mechanism 
aimed at increasing PTH secretion in 
response to hypocalcemia. According to 
this scenario, increased expression of 
klotho in early stages of CKD could allow 
an increase in its binding to the   1-subu-
nit of the enzyme and its subsequent 
enhanced translocation to the para-
thyroid-cell membrane. This in turn 
would enhance Na   +   / K   +   -ATPase activity 
and favor increased PTH secretion (see 
above). Th is mechanism would be coun-
tered by the upregulation of FGFR1 IIIC 
together with its co-receptor klotho, favor-
ing a decrease in PTH secretion in 
response to FGF23. In later stages of CKD 
the opposite would occur, as a result of 
downregulation of both klotho and FGFR 
expression. This hypothetical scenario 
could be called a yin – yang situation, as 
schematically illustrated in  Figure 1 . Th us 
in the yin situation enhanced PTH secre-
tion would mainly be due to a fully active 
klotho – Na   +   / K   +   -ATPase interaction path-
way despite concomitant inhibition 
via the FGFR pathway. In contrast, in the 
yang situation the normal inhibition of 
PTH secretion via the FGFR pathway 
would not work well or not work at all in 
case of klotho downregulation, and this 
stimulation of the parathyroid would not 
be overcome by a lower activity of the 
klotho – Na   +   / K   +   -ATPase pathway. It 
might explain why secondary hyperpar-
athyroidism evolves unabated in CKD —
 because of ongoing stimulation of PTH 
synthesis and secretion and only partially 
effi  cient counterregulatory mechanisms. 
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binding to the   1-subunit of the Na   +   / K   +   -ATPase enzyme and an increase in its abundance in the 
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 Drug research and development facil-
itates the synthesis and release of novel 
therapeutics into clinical practice at a 
re markable rate. Th eir availability has 
undoubtedly revolutionized the treatment 
of numerous diseases — in particular, dev-
astating processes such as HIV infection. 
Th e landscape of this disease has been 
forever changed by the availability of 
highly active antiretroviral therapy 
(HAART) since 1996. Th e basic premise 
behind this strategy is to attack the virus 
at diff erent replication steps using multi-
ple medications. Unfortunately, most suc-
cess stories have a catch; in this case, the 
price of success is drug-induced kidney 
disease, a challenging complication for 
HIV   +   patients and their caregivers. 1 
 Before the widespread use of HAART, 
HIV-associated kidney disease was 
 primarily due to direct and / or indirect 
eff ects of the virus. However, with success-
ful treatment of HIV infection, drug-
induced nephrotoxicity ( Table 1 ) surfaced 
as an important problem. Acute kidney 
injury (AKI), various tubulopathies, 
 nephrolithiasis, and chronic kidney 
 disease were noted. 1 HAART causes these 
renal syndromes via multiple mecha-
nisms, including direct tubular toxicity, 
allergic reactions, and precipitation of 
insoluble drug crystals. 
 Although many of the early drugs had 
intolerable adverse eff ects and diffi  cult 
dosing schedules, newer agents have over-
come many of these issues. One such 
drug, tenofovir, has gained widespread 
use on the basis of its effi  cacy, tolerability, 
and patient-friendly dosing schedule. 2 As 
it is structurally similar to the acyclic 
nucleotide analogs adefovir and cidofovir, 
which are nephrotoxic, concern about 
adverse renal eff ects existed for tenofovir 
as well. Th ese two drugs cause proximal 
tubulopathies such as AKI as a result 
of acute tubular necrosis (ATN) and 
Fanconi ’ s syndrome, 3 by disrupting proxi-
mal tubular mitochondrial function. A 
number of mechanisms underlie drug-
induced mitochondriopathies, but these 
drugs act primarily by decreasing mito-
chondrial DNA (mtDNA) replication by 
inhibiting mitochondrial DNA poly-
merase-  , which is the only enzyme capa-
ble of replicating mtDNA. 3 As a result, 
mtDNA and a number of the mtDNA-
encoded enzymes involved in electron 
transport chain function and oxidative 
phosphorylation are depleted, resulting in 
disturbed mitochondrial function. Th is 
ultimately causes, among other eff ects, a 
defi cit in adenosine triphosphate produc-
tion, impaired cell function, and cell 
injury and / or death. 
 Early randomized clinical trials 4 and 
post-marketing data 5 examining tenofovir 
in relatively healthy HIV   +   subjects sup-
ported an excellent safety profi le, includ-
ing the absence of signifi cant renal injury. 
An  in vitro experimental study supported 
this clinical fi nding. 6 Th e investigators 
exposed various cultured human cell lines 
(liver, muscle, proximal renal tubule) to 
tenofovir. Minimal mtDNA depletion and 
insignifi cant reductions in cellular expres-
sion of the mitochondrial protein cyto-
chrome  c oxidase were noted with 
tenofovir. However, with the release of 
tenofovir into clinical practice and its use 
in HIV patients with various comorbid 
conditions, reports of nephrotoxicity 
began to surface. 7 Th ese reports described 
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